Enliven Therapeutics, Inc. (ELVN) — SC 13G/A Filings
All SC 13G/A filings from Enliven Therapeutics, Inc.. Browse 7 SC 13G/A reports with AI-powered summaries and risk analysis.
SC 13G/A Filings (7)
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
-
FMR LLC & Abigail Johnson Maintain 14.321% Stake in Enliven Therapeutics
— Feb 9, 2024 Risk: low
FMR LLC, a major investment firm, and its CEO, Abigail P. Johnson, have updated their ownership in Enliven Therapeutics, Inc. (ELVN) to 14.321% of the common st -
BML Investment Partners Amends Enliven Therapeutics Stake
— Feb 7, 2024
BML Investment Partners, L.P. has filed an Amendment No. 3 to its Schedule 13G, indicating a change in its beneficial ownership of Enliven Therapeutics, Inc. co
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX